bluuebunny/crossref_metadata_2025_split huggingface dataset:
Generation of myogenic progenitor cell-derived smooth muscle cells for sphincter regeneration
Authors: Thurner Marco , Deutsch Martin , Janke Katrin , Messner Franka , Kreutzer Christina , Beyl Stanislav , Couillard-Després Sébastien , Hering Steffen , Troppmair Jakob , Marksteiner Rainer 
Published: June 2020

AbstractBackgroundDegeneration of smooth muscles in sphincters can cause debilitating diseases such as fecal incontinence. Skeletal muscle-derived cells have been effectively used in clinics for the regeneration of the skeletal muscle sphincters, such as the external anal or urinary sphincter. However, little is known about the in vitro smooth muscle differentiation potential and in vivo regenerative potential of skeletal muscle-derived cells.MethodsMyogenic progenitor cells (MPC) were isolated from the skeletal muscle and analyzed by flow cytometry and in vitro differentiation assays. The differentiation of MPC to smooth muscle cells (MPC-SMC) was evaluated by immunofluorescence, flow cytometry, patch-clamp, collagen contraction, and microarray gene expression analysis. In vivo engraftment of MPC-SMC was monitored by transplanting reporter protein-expressing cells into the pyloric sphincter of immunodeficient mice.ResultsMPC derived from human skeletal muscle expressed mesenchymal surface markers and exhibit skeletal myogenic differentiation potential in vitro. In contrast, they lack hematopoietic surface marker, as well as adipogenic, osteogenic, and chondrogenic differentiation potential in vitro.Cultivation of MPC in smooth muscle differentiation medium significantly increases the fraction of alpha smooth muscle actin (aSMA) and smoothelin-positive cells, while leaving the number of desmin-positive cells unchanged. Smooth muscle-differentiated MPC (MPC-SMC) exhibit increased expression of smooth muscle-related genes, significantly enhanced numbers of CD146- and CD49a-positive cells, and in vitro contractility and express functional Cavand Kvchannels. MPC to MPC-SMC differentiation was also accompanied by a reduction in their skeletal muscle differentiation potential. Upon removal of the smooth muscle differentiation medium, a major fraction of MPC-SMC remained positive for aSMA, suggesting the definitive acquisition of their phenotype. Transplantation of murine MPC-SMC into the mouse pyloric sphincter revealed engraftment of MPC-SMC based on aSMA protein expression within the host smooth muscle tissue.ConclusionsOur work confirms the ability of MPC to give rise to smooth muscle cells (MPC-SMC) with a well-defined and stable phenotype. Moreover, the engraftment of in vitro-differentiated murine MPC-SMC into the pyloric sphincter in vivo underscores the potential of this cell population as a novel cell therapeutic treatment for smooth muscle regeneration of sphincters.
One molecular fingerprint to rule them all: drugs, biomolecules, and the metabolome
Authors: Capecchi Alice , Probst Daniel , Reymond Jean-Louis 
Published: June 2020

Abstract
Background
Molecular fingerprints are essential cheminformatics tools for virtual screening and mapping chemical space. Among the different types of fingerprints, substructure fingerprints perform best for small molecules such as drugs, while atom-pair fingerprints are preferable for large molecules such as peptides. However, no available fingerprint achieves good performance on both classes of molecules.

Results
Here we set out to design a new fingerprint suitable for both small and large molecules by combining substructure and atom-pair concepts. Our quest resulted in a new fingerprint called MinHashed atom-pair fingerprint up to a diameter of four bonds (MAP4). In this fingerprint the circular substructures with radii of r = 1 and r = 2 bonds around each atom in an atom-pair are written as two pairs of SMILES, each pair being combined with the topological distance separating the two central atoms. These so-called atom-pair molecular shingles are hashed, and the resulting set of hashes is MinHashed to form the MAP4 fingerprint. MAP4 significantly outperforms all other fingerprints on an extended benchmark that combines the Riniker and Landrum small molecule benchmark with a peptide benchmark recovering BLAST analogs from either scrambled or point mutation analogs. MAP4 furthermore produces well-organized chemical space tree-maps (TMAPs) for databases as diverse as DrugBank, ChEMBL, SwissProt and the Human Metabolome Database (HMBD), and differentiates between all metabolites in HMBD, over 70% of which are indistinguishable from their nearest neighbor using substructure fingerprints.

Conclusion
MAP4 is a new molecular fingerprint suitable for drugs, biomolecules, and the metabolome and can be adopted as a universal fingerprint to describe and search chemical space. The source code is available at https://github.com/reymond-group/map4 and interactive MAP4 similarity search tools and TMAPs for various databases are accessible at http://map-search.gdb.tools/ and http://tm.gdb.tools/map4/.
A comparison of nasogastric tube insertion by SORT maneuver (sniffing position, NGT orientation, contralateral rotation, and twisting movement) versus neck flexion lateral pressure in critically ill patients admitted to ICU: a prospective randomized clinical trial
Authors: Sanaie Sarvin , Mirzalou Negin , Shadvar Kamran , Golzari Samad E. J. , Soleimanpour Hassan , Shamekh Ali , Bettampadi Deepti , Safiri Saeid , Mahmoodpoor Ata 
Published: June 2020

Abstract
Background
Although many techniques have been introduced to facilitate nasogastric tube (NGT) insertion using anatomic landmarks and a group of devices, there is a lack of general consensus regarding a standard method. The current study purposed to investigate if SORT maneuver (sniffing position, NGT orientation, contralateral rotation, and twisting movement) increases the success rate of NGT correct placement versus neck flexion lateral pressure (NFLP) method.

Methods
A randomized controlled trial study was conducted in two university affiliated intensive care units (tertiary referral center). Three hundred and ninety-six critically ill patients older than 18 years of age were randomly divided into SORT (n = 200) and NFLP (n = 196) groups. The technique was classified as “failed” after the third unsuccessful attempt. Patient characteristics, success rate for the first attempt, time required for the successful first attempt and overall successful insertion time, various complications including kinking, coiling and bleeding and ease of insertion were noted as main outcomes measured.

Results
Ease of insertion was significantly better in the SORT group compared to the NFLP group (P < 0.001). The number of failed attempts was significantly higher in the NFLP group (7.5%) vs the SORT group (3.0%) (P = 0.046). The pattern of complications was not different between two study groups (P = 0.242). The odds of stage II (odds ratio (OR) = 49.9; 95% confidence interval (CI) 25.2 to 98.6), stage III (OR = 67.1; 95% CI 14.9 to 302.8)) and stage IV (OR = 11.8; 95% CI 3.4 to 41.2) ease of insertion were much higher in NFLP compared to SORT group, after adjusting for age and body mass index (BMI). The odds of failure was not significantly different in NFLP group compared to SORT group (OR = 2.3; 95% CI 0.85 to 6.3), after adjusting for age and BMI.

Conclusions
SORT technique may be considered as a promising method for successful NGT insertions in critically ill patients. However, more trials are needed to confirm the results of this study. The decision must account for individual patient and clinical factors and the operator’s experience and preference.
Trial registration: The study was registered at government registry of clinical trials in Iran (http://www.IRCT.ir) (number: IRCT20091012002582N18, 13 March 2018)
Predicting the treatment response of certolizumab for individual adult patients with rheumatoid arthritis: protocol for an individual participant data meta-analysis
Authors: Luo Yan , Chalkou Konstantina , Yamada Ryo , Funada Satoshi , Salanti Georgia , Furukawa Toshi A. 
Published: June 2020

Abstract
Background
A model that can predict treatment response for a patient with specific baseline characteristics would help decision-making in personalized medicine. The aim of the study is to develop such a model in the treatment of rheumatoid arthritis (RA) patients who receive certolizumab (CTZ) plus methotrexate (MTX) therapy, using individual participant data meta-analysis (IPD-MA).

Methods
We will search Cochrane CENTRAL, PubMed, and Scopus as well as clinical trial registries, drug regulatory agency reports, and the pharmaceutical company websites from their inception onwards to obtain randomized controlled trials (RCTs) investigating CTZ plus MTX compared with MTX alone in treating RA. We will request the individual-level data of these trials from an independent platform (http://vivli.org). The primary outcome is efficacy defined as achieving either remission (based on ACR-EULAR Boolean or index-based remission definition) or low disease activity (based on either of the validated composite disease activity measures). The secondary outcomes include ACR50 (50% improvement based on ACR core set variables) and adverse events. We will use a two-stage approach to develop the prediction model. First, we will construct a risk model for the outcomes via logistic regression to estimate the baseline risk scores. We will include baseline demographic, clinical, and biochemical features as covariates for this model. Next, we will develop a meta-regression model for treatment effects, in which the stage 1 risk score will be used both as a prognostic factor and as an effect modifier. We will calculate the probability of having the outcome for a new patient based on the model, which will allow estimation of the absolute and relative treatment effect. We will use R for our analyses, except for the second stage which will be performed in a Bayesian setting using .

Discussion
This is a study protocol for developing a model to predict treatment response for RA patients receiving CTZ plus MTX in comparison with MTX alone, using a two-stage approach based on IPD-MA. The study will use a new modeling approach, which aims at retaining the statistical power. The model may help clinicians individualize treatment for particular patients.

Systematic review registration
PROSPERO registration number pending (ID#157595).
Some parameterized inequalities by means of fractional integrals with exponential kernels and their applications
Authors: Zhou Tai-Chun , Yuan Zheng-Rong , Yang Hong-Ying , Du Ting-Song 
Published: June 2020

AbstractWe use the definition of a new class of fractional integral operators, recently introduced by Ahmad et al. in [J. Comput. Appl. Math. 353:120–129, 2019], to establish a fractional-type integral identity with one parameter. We derive some parameterized integral inequalities for convex mappings based on this identity, and provide two examples to illustrate the investigated results as well. Moreover, we present applications of our findings to special means of real numbers, and error estimations for the quadrature formula in numerical analysis.
Time-space variable-order fractional nonlinear system of thermoelasticity: numerical treatment
Authors: Assiri Taghreed A. 
Published: June 2020

AbstractThis paper focuses on a numerical study of the general time-space variable-order fractional nonlinear problem of thermoelasticity in one dimension using the weighted average nonstandard finite difference (WANSFD). By replacing the second order space derivative with a Riesz fractional variable-order derivative and the time derivative by Caputo fractional variable-order operator in the standard system which arises in thermoelasticity, we obtain this general system. Using a kind of John von Neumann technique, we study the stability of the designed schemes. Also, the truncation error of the introduced schemes is studied. Our numerical treatment is shown graphically. These results expose that WANSFD approach is suitable and effective for solving the proposed system; moreover, it is easy to implement.
Weighted pseudo almost periodic solutions for Clifford-valued neutral-type neural networks with leakage delays on time scales
Authors: Shen Shiping , Li Yongkun 
Published: June 2020

AbstractIn this paper, we consider a class of Clifford-valued neutral-type neural networks with leakage delays on time scales. We do not decompose the networks under consideration into real-valued systems, but we directly study the Clifford-valued networks. We first establish the existence of weighted pseudo almost periodic solutions of this class of neural networks by the theory of calculus on time scales and the Banach fixed point theorem. Then, we study the global exponential stability of weighted pseudo almost periodic solutions of this class of neural networks by using inequality techniques and the proof by contradiction. Finally, we give an example to illustrate the feasibility of the obtained results.
Autism Spectrum Social Stories In Schools Trial 2 (ASSSIST2): study protocol for a randomised controlled trial analysing clinical and cost-effectiveness of Social Stories™ in primary schools
Authors: Wright B. , Teige C. , Watson J. , Hodkinson R. , Marshall D. , Varley D. , Allgar V. , Mandefield L. , Parrott S. , Kingsley E. , Hargate R. , Mitchell N. , Ali S. , McMillan D. , Wang H. , Hewitt C. 
Published: June 2020

Abstract
Background
Interventions designed to support children with a diagnosis of Autism Spectrum Conditions (ASC) can be time consuming, needing involvement of outside experts. Social Stories™ are a highly personalised intervention aiming to give children with ASC social information or describing an otherwise difficult situation or skill. This can be delivered daily by staff in education settings. Studies examining Social Story™ use have yielded mostly positive results but have largely been single case studies with a lack of randomised controlled trials (RCTs). Despite this numerous schools are utilising Social Stories™, and a fully powered RCT is timely.

Methods
A multi-site pragmatic cluster RCT comparing care as usual with Social Stories™ and care as usual. This study will recruit 278 participants (aged 4–11) with a clinical diagnosis of ASC, currently attending primary school in the North of England. Approximately 278 school based staff will be recruited to provide school based information about participating children with approximately 140 recruited to deliver the intervention. The study will be cluster randomised by school. Potential participants will be screened for eligibility prior to giving informed consent. Follow up data will be collected at 6 weeks and 6 months post randomisation and will assess changes in participants’ social responsiveness, goal based outcomes, social and emotional health. The primary outcome measure is the Social Responsiveness Scale Second Edition (SRS-2) completed by school based staff at 6 months. Approvals have been obtained from the University of York’s Research Governance Committee, Research Ethics Committee and the Health Research Authority. Study results will be submitted for publication in peer-reviewed journals and disseminated to participating families, educational staff, local authority representatives, community groups and Patient and Participant Involvement representatives. Suggestions will be made to NICE about treatment evidence dependent on findings.

Discussion
This study addresses a much used but currently under researched intervention and results will inform school based support for primary school children with a diagnosis of ASC.

Trial registration
The trial is registered on the ISRCTN registry (registration number: ISRCTN11634810). The trial was retrospectively registered on 23rd April 2019.
Bike helmets prevent pediatric head injury in serious bicycle crashes with motor vehicles
Authors: Strotmeyer Stephen J. , Behr Christopher , Fabio Anthony , Gaines Barbara A. 
Published: June 2020

Abstract
Background
Approximately 75% of all bicycle-related mortality is secondary to head injuries, 85% of which could have been prevented by wearing a bicycle helmet. Younger children appear to be at greater risk than adults, yet helmet use is low despite this risk and legislation and ordinances requiring helmet use among younger riders. We sought to determine whether bicycle helmets are associated with the incidence and severity of head injury among pediatric bicyclists involved in a bicycle crash involving a motor vehicle.

Methods
We performed a retrospective review of patients age ≤ 18 years hospitalized at a level I pediatric trauma center between January 1, 2008, and December 31, 2018. Data were abstracted from the institutional trauma registry and electronic medical record. International Classification of Diseases 9th and 10th editions and external causes of injury codes were used to identify MV related bicycle crashes and determine the abbreviated injury severity (AIS) for head injury severity. Injury narratives were reviewed to determine helmet use. We calculated the incidence of head injury from bicycle vs. MV crashes utilizing descriptive statistics. We analyzed the risk and severity of injury utilizing univariate and multivariate logistic regression.

Results
Overall, 226 bicyclists were treated for injuries from being struck by a MV. The median age was 11 (interquartile range (IQR): 8 to 13) years. Helmeted bicyclists (n = 26, 27%) were younger (9.4 years versus 10.8 years, p = 0.04), and were less likely (OR 0.21, 95% CI 0.09 to 0.49) to be diagnosed with a head injury compared to unhelmeted bicyclists (n = 199). Of those with a head injury, helmeted bicyclists were less likely (OR 0.57, 95% CI 0.11–2.82) to sustain severe or higher injury using AIS. When adjusting for demographics (age, sex, race) and injury severity, helmet use predicted a reduction in head injury (OR 6.02, 95% CI 2.4–15.2).

Conclusions
Bicycle helmet use was associated with reduced odds of head injury and severity of injury.. These results support the use of strategies to increase the uptake of bicycle helmets wearing as part of a comprehensive youth bicycling injury prevention program.
Successful surgical treatment for nonocclusive mesenteric ischemia of a wide area of the intestine accompanied by gastric conduit necrosis after esophagectomy for esophageal cancer: a case report and review of the literature
Authors: Miura Kotaro , Kubo Naoshi , Sakurai Katsunobu , Tamamori Yutaka , Murata Akihiro , Nishii Takafumi , Kodai Shintaro , Tachimori Akiko , Shimizu Sadatoshi , Kanazawa Akishige , Inoue Toru , Nishiguchi Yukio , Maeda Kiyoshi 
Published: June 2020

Abstract
Background
Nonocclusive mesenteric ischemia (NOMI) has been reported to be a life-threating disease. Gastric conduit necrosis is known as a critical postoperative complication after esophagectomy for esophageal cancer. We encountered a rare case of NOMI of a wide area of the intestine accompanied by gastric conduit necrosis after esophagectomy, which was successfully treated with an emergency operation.

Case presentation
A 67-year-old man presented with dysphagia. He was diagnosed with middle thoracic advanced esophageal cancer. After neoadjuvant chemotherapy, he underwent subtotal esophagectomy with lymphadenectomy and gastric conduit reconstruction. On postoperative day (POD) 2, he had diarrhea, high fever, and low blood pressure, which were treated with catecholamines. Laboratory data revealed acidosis and severe sepsis with multi-organ failure, including the kidneys. Although enhanced computed tomography did not exhibit definite findings of bowel ischemia, upper gastrointestinal endoscopy revealed necrotic mucosal changes in the whole gastric conduit. Therefore, we made a diagnosis of septic shock caused by gastric conduit necrosis and performed an emergency operation. When we explored the abdominal cavity, we found not only gastric conduit necrosis but also intermittent necrotic changes in the intestinal wall from the jejunum to the rectum. Therefore, NOMI was diagnosed. We performed an excision of the gastric conduit and 2 m of the small intestine, as well as total colectomy. After the second operation, prostaglandin E1 was administered intravenously as the treatment for NOMI, and sepsis was improved. On POD 122, he was self-discharged. He died of recurrence of lung metastasis from the esophageal cancer 9 months after the first operation.

Conclusion
When a patient has a critical status, including severe sepsis or severe acidosis, after esophagectomy, we should consider the possibility of NOMI in addition to gastric conduit necrosis and aim to diagnose and treat it immediately with an urgent operation.
Best MRI sequences for identifying axillary lymph node markers in patients with metastatic breast cancer: an inter-reader observational study
Authors: Samreen Naziya , Bhatt Asha A. , Adler Kalie , Zingula Shannon , Glazebrook Katrina N. 
Published: June 2020

Abstract
Background
We assessed confidence in visualization of markers within metastatic axillary lymph nodes (LNs) on magnetic resonance imaging (MRI), which were placed post-ultrasound (US)-guided biopsy.

Methods
A retrospective review was performed on 55 MRI cases between May 2015 and October 2017. Twenty-two MRIs were performed before neoadjuvant therapy, and 33 MRIs were after its initiation. There were 34/55 HydroMARK®, 10/55 Tumark®, and 11/55 other marker types. Time interval between marker placement and MRI examination was 103 ± 81 days (mean ± standard deviation). Three readers with 1–30 years of experience independently assessed four axial sequences: unenhanced fat-suppressed three-dimensional T1-weighted spoiled gradient-recalled (SPGR), first contrast-enhanced fat-suppressed SPGR, T2-weighted water-only fast spin-echo (T2-WO), and T2-weighted fat-only fast-spin-echo (T2-FO).

Results
Markers were 5.2× more likely to be visualized on T2-WO than on unenhanced images (p = < 0.001), and 3.3× more likely to be visualized on contrast-enhanced than on unenhanced sequences (p = 0.009). HydroMARK markers demonstrated a 3× more likelihood of being visualized than Tumark (p = 0.003). Markers were 8.4× more likely to be visualized within morphologically abnormal LNs (p < 0.001). After 250 days post-placement, confidence in marker brightness of HydroMARK markers on T2-WO images was less than 50% (p < 0.001). Inter-rater agreement was excellent for T2-WO and contrast-enhanced SPGR, good for unenhanced SPGR, and poor for T2-FO images.

Conclusion
T2-WO and contrast-enhanced images should be used for marker identification. HydroMARK was the best visualized marker. Markers were easier to identify when placed in abnormal LNs. The visibility of HydroMARK markers was reduced with time.